These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 31185573

  • 1. An Intelligent DNA Nanorobot with in Vitro Enhanced Protein Lysosomal Degradation of HER2.
    Ma W, Zhan Y, Zhang Y, Shao X, Xie X, Mao C, Cui W, Li Q, Shi J, Li J, Fan C, Lin Y.
    Nano Lett; 2019 Jul 10; 19(7):4505-4517. PubMed ID: 31185573
    [Abstract] [Full Text] [Related]

  • 2. Enhanced Human Epidermal Growth Factor Receptor 2 Degradation in Breast Cancer Cells by Lysosome-Targeting Gold Nanoconstructs.
    Lee H, Dam DH, Ha JW, Yue J, Odom TW.
    ACS Nano; 2015 Oct 27; 9(10):9859-67. PubMed ID: 26335372
    [Abstract] [Full Text] [Related]

  • 3. Copolymer micelles function as pH-responsive nanocarriers to enhance the cytotoxicity of a HER2 aptamer in HER2-positive breast cancer cells.
    Shen Y, Zhang J, Hao W, Wang T, Liu J, Xie Y, Xu S, Liu H.
    Int J Nanomedicine; 2018 Oct 27; 13():537-553. PubMed ID: 29416334
    [Abstract] [Full Text] [Related]

  • 4. Self-Assembled Multivalent Aptamer Drug Conjugates: Enhanced Targeting and Cytotoxicity for HER2-Positive Gastric Cancer.
    Ma W, Yang Y, Liu Z, Zhao R, Wan Q, Chen X, Tang B, Zhou Y, Lin Y.
    ACS Appl Mater Interfaces; 2023 Sep 20; 15(37):43359-43373. PubMed ID: 37670592
    [Abstract] [Full Text] [Related]

  • 5. Biomimetic Nanoerythrosome-Coated Aptamer-DNA Tetrahedron/Maytansine Conjugates: pH-Responsive and Targeted Cytotoxicity for HER2-Positive Breast Cancer.
    Ma W, Yang Y, Zhu J, Jia W, Zhang T, Liu Z, Chen X, Lin Y.
    Adv Mater; 2022 Nov 20; 34(46):e2109609. PubMed ID: 35064993
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
    Xue L, Maihle NJ, Yu X, Tang SC, Liu HY.
    Mol Pharm; 2018 Nov 05; 15(11):4801-4813. PubMed ID: 30222359
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cellular uptake, intracellular distribution and degradation of Her2-targeting silk nanospheres.
    Florczak A, Mackiewicz A, Dams-Kozlowska H.
    Int J Nanomedicine; 2019 Nov 05; 14():6855-6865. PubMed ID: 32021156
    [Abstract] [Full Text] [Related]

  • 14. Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity.
    Ríos-Luci C, García-Alonso S, Díaz-Rodríguez E, Nadal-Serrano M, Arribas J, Ocaña A, Pandiella A.
    Cancer Res; 2017 Sep 01; 77(17):4639-4651. PubMed ID: 28687619
    [Abstract] [Full Text] [Related]

  • 15. Novel flexible heteroarotinoid, SL-1-39, inhibits HER2-positive breast cancer cell proliferation by promoting lysosomal degradation of HER2.
    Zou H, Sevigny MB, Liu S, Madden DT, Louie MC.
    Cancer Lett; 2019 Feb 28; 443():157-166. PubMed ID: 30503556
    [Abstract] [Full Text] [Related]

  • 16. Targeted and effective glioblastoma therapy via aptamer-modified tetrahedral framework nucleic acid-paclitaxel nanoconjugates that can pass the blood brain barrier.
    Shi S, Fu W, Lin S, Tian T, Li S, Shao X, Zhang Y, Zhang T, Tang Z, Zhou Y, Lin Y, Cai X.
    Nanomedicine; 2019 Oct 28; 21():102061. PubMed ID: 31344499
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.